Screener
ImmunityBio, Inc. IBRX Operating Lease Liability - Undiscounted Excess Amount
Operating Lease Liability - Undiscounted Excess Amount at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Years Ending December 31: | Operating Leases | Finance Leases | Total |
|---|---|---|---|
| 2028 | 11,349 | 79 | 11,428 |
| 2029 | 10,221 | 79 | 10,300 |
| 2030 | 7,837 | 34 | 7,871 |
| 2031 | 1,523 | — | 1,523 |
| Thereafter | 453 | — | 453 |
| Total future minimum lease payments | 51,269 | 330 | 51,599 |
| Less: Interest | 10,496 | 64 | 10,560 |
| Present value of lease liabilities | $40,773 | $266 | $41,039 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s operating lease liability - undiscounted excess amount?
- ImmunityBio, Inc. (IBRX) reported operating lease liability - undiscounted excess amount of $10.5M in Q1 2026.
- How has ImmunityBio, Inc.'s operating lease liability - undiscounted excess amount changed year-over-year?
- ImmunityBio, Inc.'s operating lease liability - undiscounted excess amount decreased by 13.4% year-over-year, from $12.12M to $10.5M.
- What does operating lease liability - undiscounted excess amount mean?
- This represents the difference between the total undiscounted future lease payments and the present value of those payments recorded on the balance sheet. It effectively quantifies the interest component embedded within operating lease obligations. It is a measure of the financing cost inherent in the lease portfolio.
Ask your AI about ImmunityBio, Inc.'s operating lease liability - undiscounted excess amount.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude